<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907072</url>
  </required_header>
  <id_info>
    <org_study_id>WVE-DMDX51-003</org_study_id>
    <nct_id>NCT03907072</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy</brief_title>
  <acronym>DYSTANCE 51</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wave Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an
      open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in
      ambulatory male pediatric patients with Duchenne muscular dystrophy (DMD) amenable to exon 51
      skipping intervention (DYSTANCE 51)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in dystrophin level (% normal dystrophin)</measure>
    <time_frame>Day 1 to Week 12, Week 22, or Week 46</time_frame>
    <description>US/other regions (as applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Day 1 through Week 48</time_frame>
    <description>European Union (EU)/other regions (as applicable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Day 1 through Week 48</time_frame>
    <description>US/other regions (as applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dystrophin level (% normal dystrophin)</measure>
    <time_frame>Day 1 to Week 12, Week 22, or Week 46</time_frame>
    <description>European Union (EU)/other regions (as applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in upper limb proximal strength</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 4-stair climb</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 10-meter walk/run test</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in forced vital capacity</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 95th percentile of stride velocity</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NSAA</measure>
    <time_frame>Day 1 through Week 96</time_frame>
    <description>Long-term evaluation, open label from Week 48 through Week 96</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-210201 (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WVE-210201 (suvodirsen)</intervention_name>
    <description>WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
    <arm_group_label>WVE-210201 (Dose A)</arm_group_label>
    <arm_group_label>WVE-210201 (Dose B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Buffered saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase

          2. Documented mutation in the Dystrophin gene associated with DMD that is amenable to
             exon 51 skipping

          3. Ambulatory male, able to walk independently for at least 10 meters in 10 seconds or
             less at the time of Screening visit (performed as part of the NSAA)

          4. Stable pulmonary and cardiac function, as measured by:

               1. Reproducible percent predicted forced vital capacity (FVC) ≥50%

               2. Left ventricular ejection fraction (LVEF) &gt;55% in patients &lt;10 years of age and
                  &gt;45% in patients ≥10 years of age, as measured (and documented) by echocardiogram

          5. Currently on a stable corticosteroid therapy regimen, defined as initiation of
             systemic corticosteroid therapy occurred ≥6 months prior to Screening, and no changes
             in dosing ≤3 months prior to Screening visit

        Exclusion Criteria:

          1. Cardiac insufficiency:

               1. Severe cardiomyopathy that, in the opinion of the Investigator, prohibits
                  participation in this study; however, cardiomyopathy that is managed by
                  angiotensin-converting-enzyme (ACE) inhibitors or beta blockers is acceptable
                  provided the patient meets the LVEF inclusion criterion

               2. Any other evidence of clinically significant structural or functional heart
                  abnormality

               3. A cardiac troponin I value &gt; 0.2 ng/mL

          2. Need for daytime mechanical or non-invasive ventilation OR anticipated need for
             daytime mechanical or non-invasive ventilation within the next year, in the opinion of
             the Investigator. Nighttime non-invasive ventilation is permitted

          3. Received prior treatment with drisapersen or with an investigational
             peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)

          4. Received prior treatment with gene therapy for DMD

          5. Received treatment with ataluren or eteplirsen within the 14 weeks prior to the
             planned Baseline biopsy collection

          6. Received any investigational drug within 3 months or 5 half-lives, whichever is
             longer, prior to the planned Baseline biopsy collection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Panzara, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Wave Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trosseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C di Neurologia e Malattie Neuromuscolari Centro Clinico Nemo Sud</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Reffaele Via Olgettina, 60</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>8, 00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn Och Ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>41650</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

